NSPR - InspireMD Inc

NSPR - InspireMD Inc

https://www.inspiremd.com

Recent News

Powered by Alpha Vantage

InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire • 2 weeks, 5 days ago • score: 0.28

MIAMI, Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- InspireMD, Inc. ( Nasdaq: NSPR ) , developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10th at ...

InspireMD Announces Combined Financings of $58 Million - InspireMD ( NASDAQ:NSPR )

Benzinga • 1 month, 2 weeks ago • score: 0.10

MIAMI, July 31, 2025 ( GLOBE NEWSWIRE ) -- InspireMD, Inc.

InspireMD to Announce Second Quarter 2025 Financial Results

GlobeNewswire • 1 month, 3 weeks ago • score: 0.14

MIAMI, Fla., July 22, 2025 ( GLOBE NEWSWIRE ) -- InspireMD, Inc. ( Nasdaq: NSPR ) , developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025.

InspireMD to Announce Second Quarter 2025 Financial Results - InspireMD ( NASDAQ:NSPR )

Benzinga • 1 month, 3 weeks ago • score: 0.12

MIAMI, Fla., July 22, 2025 ( GLOBE NEWSWIRE ) -- InspireMD, Inc. NSPR, developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025.

CVRx ( CVRX ) Surges 19.0%: Is This an Indication of Further Gains?

Zacks Commentary • 1 month, 4 weeks ago

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

InspireMD Launches CGuard Prime Carotid Stent System in the U.S.

Zacks Commentary • 2 months ago • score: 0.45

NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

InspireMD, Inc., a medical device company, is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular disease in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.

52W High

$3.80

52W Low

$1.99

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.68

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

11.70

EV/EBITDA (<8 favorable)

0.52

EV/Revenue (<3 favorable)

12.03

P/S (TTM) (<3 favorable)

14.29

P/B (<3 favorable)

4.99

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

18.19%

Institutions (25–75% balanced)

32.86%

Shares Outstanding

41,720,700

Float

28,846,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

7,066,000

Gross Profit (TTM)

1,488,000

EPS (TTM)

-0.81

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-7.32%

ROE (TTM) (>15% strong)

-1.24%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.02

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—